Ubiquitin-specific processing protease 1 (USP1) compounds

By providing compounds of formula (I) as USP1 inhibitors, the challenge of regulating USP1 expression or activity has been solved, enabling effective treatment of cancer, autoimmune disorders, and inflammatory disorders.

CN122180686APending Publication Date: 2026-06-09BRISTOL MYERS SQUIBB CO
View PDF 33 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BRISTOL MYERS SQUIBB CO
Filing Date
2024-10-30
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively regulate the expression or activity of ubiquitin-specific protease 1 (USP1), making related diseases such as cancer, autoimmune disorders, and inflammatory disorders difficult to treat.

Method used

Compounds of formula (I) and their pharmaceutically acceptable salts, stereoisomers, etc., are provided as USP1 inhibitors for regulating the expression or activity of USP1, preparing pharmaceutical compositions and administering them to treat related diseases.

Benefits of technology

By inhibiting USP1, the compound can effectively treat USP1-mediated diseases, including cancer, autoimmune and inflammatory disorders, and provides a variety of specific compound structures to achieve therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122180686A_ABST
    Figure CN122180686A_ABST
Patent Text Reader

Abstract

Compounds having the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, are USP1 inhibitors useful for treating diseases, including treating proliferative, metabolic, allergic, autoimmune, and inflammatory diseases. Formula (I).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Small molecule inhibitors of USP1 deubiquitinating enzyme activity

    US9518032B2

  • Casier à bouteilles

    WO024360

  • Anti-ox40l antibodies

    WO2006029879A2

  • GITR binding molecules and uses therefor

    WO2006105021A2

  • Modulators of indoleamine 2,3-dioxygenase and methods of using the same

    WO2006122150A1